FindTrial
Sign In

An Open-Label Dose Escalation Study to Assess the Safety and Tolerability of a Single Intravitreal Injection of SPVN20 Gene Therapy in Subjects with No Light Perception Due to End Stage Rod Cone Dystrophy, and Who Retain Dormant Foveal Cone Photoreceptors

Status
Recruiting
Phases
Phase 1
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2025-520665-47-00
Acronym
SPVN20-CLIN-01
Enrollment
7
Registered
2025-05-27
Start date
2025-10-08
Completion date
Unknown
Last updated
2025-12-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

End-stage rod-cone dystrophy

Interventions

None listed

Sponsors

Sparingvision
Lead SponsorINDUSTRY

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Countries

Belgium, France, Ireland

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026